29 Sep 2019
ESMO 2019: Efficacy and Safety of Surufatinib in Patients with Well-Differentiated Advanced Extrapancreatic NETs
Upcoming Investor Events
Learn More
THE LANCET :
FRESCO-2, a global Phase III study of fruquintinib in refractory metastatic colorectal cancer
Learn More
THE LANCET HAEMATOLOGY:
Sovleplenib for primary immune thrombocytopenia patients in China
Learn More
European Lung Cancer Congress 2022
Final OS results and subgroup analysis of savolitinib Phase II study in METex14+ NSCLC
Learn More
Latest News
29 Sep 2021HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual MeetingRead more 29 Sep 2021HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint VentureRead more 21 Sep 2021HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in ChinaRead more
20 Sep 2021HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine TumorsRead more 13 Sep 2021HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular LymphomaRead more 8 Sep 2021HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in ChinaRead more 7 Sep 2021HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual ConferenceRead more See all
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
LONDON AIM
13
HKEX
13
IN-HOUSE DISCOVERED
CLINICAL STAGE CANCER
DRUG CANDIDATES
CLINICAL STAGE CANCER
DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE U.S.
PRODUCT IN THE U.S.
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13 REGISTRATION STUDIES
INCLUDING 13 REGISTRATION STUDIES
5,000
PERSONNEL ACROSS
THE GROUP
THE GROUP
OUR SCIENCE
Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.
FOLLOW HUTCHMED ON SOCIAL MEDIA
